Panitumumab: adverse event reports filed with FDA

5,664

reports as suspect product

0% of all reports · about 274 a year

220

reports, 12 months to June 2026

233 in the 12 months before

98%

marked serious by the reporter

85.5% across the class

20.9%

record death among outcomes, as reported

1,182 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Panitumumab reports recording the termmedian drug in epidermal growth factor receptor antagonist

1. Diarrhoealoose or frequent stools14.3%808
2. Neutropenialow neutrophils, a type of white blood cell8.8%501
3. Dermatitis acneiform8.6%489
4. Rashskin rash7.5%426
5. Deaththe patient died; cause not stated by this term7.1%400
6. Nauseafeeling sick6.9%390
7. Hypomagnesaemialow blood magnesium6%339
8. Stomatitissore mouth5.9%335
9. Colorectal cancer metastatic5.8%327
10. Skin toxicity5.3%302
11. Vomitingbeing sick5.3%298
12. Decreased appetitereduced appetite5.2%297
13. Fatiguetiredness5.2%297
14. Thrombocytopenialow platelets5.2%295
15. Paronychia5.2%294
16. Anaemialow red blood cells5%286
17. Neuropathy peripheralnerve damage in hands or feet4.9%280
18. Off label useused for a purpose or in a way not on the label4.4%251
19. Disease progressionthe disease advanced4.4%249
20. Febrile neutropeniafever with low white blood cells3.8%214
21. Astheniaweakness or lack of energy3.7%212
22. Pyrexiafever3.7%212
23. Dehydrationdehydration3.7%208
24. Therapy partial responder3.6%206
25. Dry skindry skin3.5%196
26. Mucosal inflammation3.3%187
27. Metastases to liver3.2%179
28. Colorectal cancer2.9%162
29. Pulmonary embolisma blood clot in the lung2.7%152
30. Interstitial lung diseasescarring or inflammation of lung tissue2.6%145

Top 30 of 749 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 4 drugs in the epidermal growth factor receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 43,907 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 15.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,664 reports.

Drugs most often listed in the same reports

Other products listed in reports where Panitumumab is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the epidermal growth factor receptor antagonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Panitumumab as a suspect or interacting product; reports listing it only as a concomitant medication (426) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.